Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

• Published in: Clinical cancer research Vol. 23; no. 12; pp. 3012 - 3024
• Main Authors: Dong, Zhong-Yi, Zhong, Wen-Zhao, Zhang, Xu-Chao, Su, Jian, Xie, Zhi, Liu, Si-Yang, Tu, Hai-Yan, Chen, Hua-Jun, Sun, Yue-Li, Zhou, Qing, Yang, Jin-Ji, Yang, Xue-Ning, Lin, Jia-Xin, Yan, Hong-Hong, Zhai, Hao-Ran, Yan, Li-Xu, Liao, Ri-Qiang, Wu, Si-Pei, Wu, Yi-Long
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research Inc 15.06.2017
• Subjects: Adenocarcinoma; Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - immunology; Adenocarcinoma - pathology; Adenocarcinoma of Lung; Apoptosis; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - genetics; Biomarkers, Tumor - genetics; Cancer; Cell death; Deoxyribonucleic acid; DNA; DNA biosynthesis; DNA damage; DNA repair; Experimental design; Female; Gene expression; Gene set enrichment analysis; Humans; Immune checkpoint; Immunotherapy; Interferon; K-Ras protein; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Lungs; Male; Mutation; Non-small cell lung carcinoma; p53 Protein; Patients; PD-1 protein; PD-L1 protein; Prognosis; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - genetics; Proteomics; Proto-Oncogene Proteins p21(ras) - genetics; Signaling; Subgroups; Transversion; Tumor Suppressor Protein p53 - genetics; Tumors

Purpose: Although clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and ligand (PD-L1) signaling in non–small cell lung cancer (NSCLC), the factors that predict which subtype patients will be responsive to checkpoint blockade are not fully understood. Experimen...